Literature DB >> 2792144

Single-photon emission computed tomography studies with 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine.

L Battistin1, G Pizzolato, M Dam, C Da Col, N Perlotto, B Saitta, N Borsato, M Calvani, G Ferlin.   

Abstract

The acute effects of intravenously administered L-acetylcarnitine (LAC) were evaluated with single-photon emission computed tomography (SPECT) and 99mTc-hexamethylpropyleneamine oxime in 30 demented patients (21 with a clinical diagnosis of Alzheimer's dementia and 9 with mixed-type dementia). Two SPECT scans were performed: in basal conditions, and 30 min after the administration of 500, 1,000, 1,500, or 2,000 mg LAC intravenously. Tracer activity ratios were determined in 10 pairs of cerebellar, cortical and subcortical regions. After administration of the lowest dose of LAC, no changes from the basal values were observed in any of the regions examined. The higher doses of the drug significantly elevated the tracer activity in cortical regions, particularly in the parietal lobe, which showed an impaired regional cerebral blood flow in the basal study. These effects of LAC and their relation with the cholinomimetic properties of the drug are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2792144     DOI: 10.1159/000116423

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  6 in total

1.  Demonstration of human motor cortex activation using SPECT.

Authors:  M S George; H A Ring; D C Costa; K Kouris; P J Ell
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  Brain perfusion SPECT in patients with mild cognitive impairment and Alzheimer's disease: comparison of a semiquantitative and a visual evaluation.

Authors:  W Staffen; U Schönauer; H Zauner; I Spindler; A Mair; B Iglseder; G Bernroider; G Ladurner
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

3.  L-carnitine exposure and mitochondrial function in human neuronal cells.

Authors:  David A Geier; Mark R Geier
Journal:  Neurochem Res       Date:  2013-09-05       Impact factor: 3.996

Review 4.  Neuroimaging in Alzheimer's disease: relevance for treatment.

Authors:  C H van Dyck
Journal:  Curr Psychiatry Rep       Date:  2001-02       Impact factor: 5.285

5.  A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders.

Authors:  David A Geier; Janet K Kern; Georgia Davis; Paul G King; James B Adams; John L Young; Mark R Geier
Journal:  Med Sci Monit       Date:  2011-06

Review 6.  Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.

Authors:  Manuela Pennisi; Giuseppe Lanza; Mariagiovanna Cantone; Emanuele D'Amico; Francesco Fisicaro; Valentina Puglisi; Luisa Vinciguerra; Rita Bella; Enzo Vicari; Giulia Malaguarnera
Journal:  Nutrients       Date:  2020-05-12       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.